Introduction: There is a lack of agreed and established guidelines for the treatment of acute
INTRODUCTION
The most common form of idiopathic interstitial pneumonia (IIP) is idiopathic pulmonary fibrosis (IPF) [1, 2] , accounting for almost 25% of all interstitial lung diseases (ILD) [3, 4] . IPF is a chronic, progressive, and irreversible life-limiting condition. Prognosis is poor, with many patients surviving less than 3-5 years following diagnosis [5] [6] [7] . IPF is typically characterized clinically by progressive dyspnea with worsening respiratory status [1, 2] , resulting in progressive functional limitation and poor health-related quality of life (HRQoL) [8] . IPF is most common in middle-aged and older adults [2, 9] , with five times more men than women being diagnosed with the condition [10, 11] . Environmental factors, such as cigarette smoking and occupational exposures, are often cited as triggers for the development of IPF, with recent research indicating that a family history of fibrosis may be the strongest risk factor [12] . However, the exact etiology of the condition is currently unknown [13] . Within the United Kingdom (UK), the incidence of IPF was estimated to be 6.8 per 100,000 in 2000-2003 [14] . Global estimates suggest an incidence of 14-43 per 100,000 [15] , resulting in approximately 5 million sufferers worldwide [16] , a burden which, it is suggested, will continue to increase [17] .
IPF progression is associated with unpredictable acute deteriorations in respiratory function which are not associated with any identifiable cause such as infection, pulmonary embolism, or heart failure [18] .
These episodes are termed acute exacerbations of IPF (AE-IPF) [19, 20] and frequently result in premature death. Mortality rate in the year following an AE-IPF is reported to be as high as 80% [13] . The American Thoracic Society (ATS) and European Respiratory Society (ERS) working groups have provided diagnostic criteria and guidelines for identifying possible AE-IPF. Despite the terminology and criteria proposed [2] , guidance on the real-world diagnosis and treatment of AE-IPF is largely absent from IPF guidelines. For example, AE-IPF was absent from the 2000 ATS/ERS international consensus statement [2] . AE-IPF was mentioned, but not defined nor discussed, in the 2002 ATS/ERS international multidisciplinary consensus statement [21] , and only briefly discussed within the 2011 ATS/ERS/Japanese Respiratory Society/Latin American Thoracic Association statement [22] .
There are a number of important barriers impeding the management and treatment of patients with AE-IPF. Despite the 2007 guidelines outlined by Collard et al. [23] , there remains a lack of consensus in defining AE-IPF, especially relating to excluding, or understanding, the role of infection in the pathogenesis of the condition. In the absence of an agreed definition, there is a lack of clear guidelines for diagnosing and treating AE-IPF [24] .
Consensus methods such as the Delphi technique are widely used and accepted for medical and health service research [25] [26] [27] [28] [29] [30] . For example, the Delphi technique has recently been used in the development of international clinical practice statements for the treatment of neuropsychiatric conditions associated with epilepsy [31] and cystic fibrosis pulmonary guidelines [32] . This specific technique is often used in circumstances when there are gaps or contradictions in knowledge [25] .
The primary objective of this study was to use the Delphi technique to develop a consensus statement for the definition, diagnosis, and treatment of AE-IPF to guide clinicians in efficient diagnosis and treatment.
METHODS
A structured literature review was conducted using Medline, PsycINFO, and EMBASE with a supplemental search of grey literature, to generate published materials that could contribute an initial list of statements to enter the Delphi process. The review focused on three specific areas: current opinion on the definition and diagnosis of AE-IPF; consensus or agreement on the treatment of patients with AE-IPF; and current treatment options for patients with AE-IPF. The search specifically targeted English language articles published between 2003 and October 2013 using search terms that were reviewed and agreed with clinicians participating in the Delphi process (Table 1) .
Following completion of the literature review, a panel of ten experts was invited to participate in an online forum. These experts were all practicing clinicians with experience in treating patients with IPF. The purpose of the online forum was to explore the results from the literature review and discuss additional themes that might be appropriate for inclusion in a consensus statement. [34] . Participants reviewed and commented on the statements in isolation and all responses were anonymized, ensuring each participant provided their own opinion without influence [25] . For each statement, all ten participants were asked to judge whether the statement was clear ('yes' or 'no'), whether they believed that the statement should be included
(1 = 'definitely not include' to 9 = 'definitely include'), and finally to provide any comments, in the form of free text, that might help clarify the meaning of the statement (Fig. 1 ).
Using the criteria in Table 2 , all statements were analyzed to determine whether the statement should be considered for inclusion, with or without modification [35] . All ten clinicians participated in round one and two, and nine clinicians participated in round three. 
RESULTS
The literature search strategy ( Fig. 2 [39, 40] , antibiotics [38] , tyrosine kinase receptor inhibitor [44] , anti-coagulation therapy [23, 40] , and non-pharmacological treatments such as polymyxin B-immobilized fiber column treatment [36, 37, 40] , mechanical ventilation [38, 40, 46] , and lung transplantation [40] . Seven participants took part in the online forum with five of these also participating in a face-to-face meeting to discuss clinically meaningful ways to define AE-IPF and its treatment. Following the online forum and face-to-face meeting, 65 statements were developed. These addressed AE-IPF definition, AE-IPF acute treatment including supportive measures, anti-microbials, immunosuppressants, anti-coagulants, anti-fibrotic therapy, escalation, Ten senior respiratory consultants participated in the initial and second rounds of the Delphi survey. Nine participated in the third and final rounds. All participants were experienced in treating patients with AE-IPF (Table 3) .
Following round 1 review of the 65 statements, 10 were deleted, 29 revised, and 26 remained unmodified (Table 4) . AE-IPF definition statements were revised such that infection was excluded 'as far as possible' rather than 'per routine clinical practice'. As such, an anti-infective treatment path statement was also revised to include a footnote that negative diagnosis is never completely certain.
Additionally, references to specific doses of treatments were removed. All deleted statements in round one were excluded due to low ratings. (Table 4) . Statements were deleted from oxygen supportive measures, treatment paths, anti-reflux therapy, and anti-infective topics due to their low ratings.
The final consensus statement is presented in Table 5 . The single statement revision in round three was a grammatical change to enhance clarity. Statements were deleted at each round either due to low ratings or conceptual overlapping with other statements. If a patient has recently been admitted as an inpatient they should additionally be covered for hospital acquired infection Anti-virals should not be prescribed routinely but only in cases of strong clinical suspicion and in accordance with local guidelines
Immunosuppressants
Corticosteroids should be considered in all patients unless specifically contra-indicated
Long-term corticosteroid dosing should be determined based on the individual patient
Cyclophosphamide/azathioprine/MMF should not be prescribed
The use of biologics, e.g., rituximab, is not recommended
Anti-coagulants
LMW heparin and/or anticoagulants should be initiated prophylactically to prevent DVT according to standard hospital policy, unless patients are already receiving anticoagulation therapy If patients recover from AE-IPF review suitability for transplant referral, ideally at an early follow-up appointment in the clinic
Long-term management
Appropriate long-term management is essential following AE-IPF by a clinician with specialist expertise in IPF management
As part of long-term management a review should assess the need for transplant referral
As part of long-term management a review should assess the need for anti-fibrotic treatment
As part of long-term management a review should assess the suitability for inclusion in clinical trials
As part of long-term management a review by a respiratory physiotherapist should assess the need for pulmonary rehabilitation Appropriate supportive and palliative care mechanisms should be put in place
Discharge planning
Discharge planning should ensure adequate home oxygen is in place prior to discharge if required Discharge planning should ensure an early post-discharge review at an ILD clinic is in place (within 4-6 weeks)
An appropriate discharge letter should be provided
Preventative therapies
There is no clear evidence to provide recommendations for preventative therapies at present
Additional information
Note that this is an opinion-led standard of care and that there is an absence of an evidence base AE-IPF acute exacerbations of idiopathic pulmonary fibrosis, CPAP continuous positive airway pressure, DVT deep venous thrombosis, HRCT high-resolution computed tomography, ILD interstitial lung disease, LMW low molecular weight, MMF mycophenolate mofetil, PE pulmonary embolism, SpO 2 peripheral oxygen saturation a Negative diagnosis is never completely certain [47] or social judgment analysis [48] , was considered a more appropriate approach because of lack of clinical guidelines currently in the literature. As a consensus method, the Compliance with ethics guidelines. All 
DISCUSSION

